Arnoud J. Templeton

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Stefan Diem, Sabine Schmid, M. Krapf et al. · Lung Cancer · 2017 · 992 citations

Medicine, Immunology, Pathology +8

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic

Girish S. Kulkarni, Thomas Hermanns, Yanliang Wei et al. · Journal of Clinical Oncology · 2017 · 295 citations · Full text

Tmt Group, Urology, Surgical Oncology +15

Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer

Igor Cima, Ralph Schiess, Peter J. Wild et al. · Proceedings of the National Academy of Sciences · 2011 · 191 citations

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

David Lorente, Joaquı́n Mateo, Arnoud J. Templeton et al. · Annals of Oncology · 2014 · 188 citations · Full text

Urology, Baseline Neutrophil–lymphocyte Ratio, Medicine +7

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy

Arnoud J. Templeton, Jennifer J. Knox, Xun Lin et al. · European Urology · 2016 · 147 citations · Full text

Urology, Cancer Immunosurveillance, Genitourinary Cancer +8